ECP
RNAM

Empyrean Capital Partners’s Avidity Biosciences RNAM Stock Holding History

Empyrean Capital Partners’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-143,000
Closed -$10.3M – 133
2025
Q4 		$10.3M Buy
+143,000
New +$9.24M 0.36% 68

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

Empyrean Capital Partners's RNAM Position: Q1 2026 in Review

Empyrean Capital Partners sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 143,000 shares — an estimated $10.3M sold.

Empyrean Capital Partners first reported a position in RNAM in Q4 2025 and held it in 1 quarter. The position peaked at $10.3M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Empyrean Capital Partners reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Empyrean Capital Partners sold 143,000 Avidity Biosciences shares in Q1 2026, an estimated $10.3M.
  • Empyrean Capital Partners first reported a position in Avidity Biosciences in Q4 2025 and held it in 1 quarter.
  • Empyrean Capital Partners's Avidity Biosciences position peaked at $10.3M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Empyrean Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.